drugset / Trial / NCT00867685

Phase I 2-Way Crossover Study to Assess Relative BA of Tablet Versus Liquid Suspension and Food Effect on Tablet Formulation

NCT00867685

Phase 1 Completed 16 enrolled AstraZeneca
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to compare the liquid suspension form of AZD 2624 to a tablet form of the same drug. This study will also study the effect of food on the tablet form of the drug.

Timeline

Start
2009-03
Primary completion
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject PAVINETANT Small molecule 40 mg Oral

Indications

No indication recorded.